These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24045230)

  • 61. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
    Yuan T; Li J; Zhang MY
    MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization.
    Wu SC; Lin YJ; Chou JW; Lin CW
    Vaccine; 2004 Nov; 23(2):163-71. PubMed ID: 15531033
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Similar binding properties for a neutralizing anti-tetanus toxoid human monoclonal antibody and its bacterially expressed Fab.
    Lafaye P; Nato F; Mazié JC; Doyen N
    Res Immunol; 1995; 146(6):373-82. PubMed ID: 8719661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
    Burton DR; Barbas CF; Persson MA; Koenig S; Chanock RM; Lerner RA
    Proc Natl Acad Sci U S A; 1991 Nov; 88(22):10134-7. PubMed ID: 1719545
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.
    Gorman J; Chuang GY; Lai YT; Shen CH; Boyington JC; Druz A; Geng H; Louder MK; McKee K; Rawi R; Verardi R; Yang Y; Zhang B; Doria-Rose NA; Lin B; Moore PL; Morris L; Shapiro L; Mascola JR; Kwong PD
    Cell Rep; 2020 Apr; 31(1):107488. PubMed ID: 32268107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of human immunodeficiency virus type 1 integrase by the Fab fragment of a specific monoclonal antibody suggests that different multimerization states are required for different enzymatic functions.
    Barsov EV; Huber WE; Marcotrigiano J; Clark PK; Clark AD; Arnold E; Hughes SH
    J Virol; 1996 Jul; 70(7):4484-94. PubMed ID: 8676473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
    Gustchina E; Bewley CA; Clore GM
    J Virol; 2008 Oct; 82(20):10032-41. PubMed ID: 18667502
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
    J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression of HIV-1 broadly neutralizing antibodies mediated by recombinant adeno-associated virus 8 in vitro and in vivo.
    Yu Y; Fu L; Jiang X; Guan S; Kuai Z; Kong W; Shi Y; Shan Y
    Mol Immunol; 2016 Dec; 80():68-77. PubMed ID: 27835755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
    Buffa V; Negri DRM; Leone P; Bona R; Borghi M; Bacigalupo I; Carlei D; Sgadari C; Ensoli B; Cara A
    J Gen Virol; 2006 Jun; 87(Pt 6):1625-1634. PubMed ID: 16690927
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.
    Yang L; Song Y; Li X; Huang X; Liu J; Ding H; Zhu P; Zhou P
    J Virol; 2012 Jul; 86(14):7662-76. PubMed ID: 22553333
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in Escherichia coli.
    Takeda S; Dorfman NA; Robert-Guroff M; Notkins AL; Rando RF
    Hybridoma; 1995 Feb; 14(1):9-18. PubMed ID: 7768538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.
    Gustchina E; Louis JM; Frisch C; Ylera F; Lechner A; Bewley CA; Clore GM
    Virology; 2009 Oct; 393(1):112-9. PubMed ID: 19695655
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA.
    Giraud A; Ataman-Onal Y; Battail N; Piga N; Brand D; Mandrand B; Verrier B
    J Virol Methods; 1999 Apr; 79(1):75-84. PubMed ID: 10328537
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.
    Bournazos S; Gazumyan A; Seaman MS; Nussenzweig MC; Ravetch JV
    Cell; 2016 Jun; 165(7):1609-1620. PubMed ID: 27315478
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
    Hamorsky KT; Grooms-Williams TW; Husk AS; Bennett LJ; Palmer KE; Matoba N
    Antimicrob Agents Chemother; 2013 May; 57(5):2076-86. PubMed ID: 23403432
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig.
    Xu Z; Wise MC; Choi H; Perales-Puchalt A; Patel A; Tello-Ruiz E; Chu JD; Muthumani K; Weiner DB
    EBioMedicine; 2018 Sep; 35():97-105. PubMed ID: 30174283
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.
    Kwon YD; Asokan M; Gorman J; Zhang B; Liu Q; Louder MK; Lin BC; McKee K; Pegu A; Verardi R; Yang ES; Program VP; Carlton K; Doria-Rose NA; Lusso P; Mascola JR; Kwong PD
    MAbs; 2021; 13(1):1946918. PubMed ID: 34328065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.